Skip to main content

23-02-2018 | Breast cancer | Article

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

De Placido S et al. Lancet Oncol 2018; 19(4): 474-485. doi:10.1016/S1470-2045(18)30116-5

Please log in to get access to this content

Related topics